All In Biotech

Drug Trial Radar · NCT07498335

Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN

A Single-arm, Multicenter, Phase III Study to Assess Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients of 2 to <18 Years of Age With Primary Immunoglobulin A Nephropathy (IgAN)

Last checked: Nov 20, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

28

Planned (sponsor's estimate)

Start

Aug 6, 2026

Primary completion

Sep 15, 2031

Study completion Dec 13, 2032

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Mar 27, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 2 years, up to 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase III, single-arm, multicenter pediatric clinical study evaluating atrasentan in children and adolescents aged 2 to \<18 years with primary immunoglobulin A nephropathy (IgAN).

Conditions

  • Berger Disease
  • Bergers Disease
  • IgA Nephropathy
  • Immunoglobulin A Nephropathy
  • Primary IgAN
  • Nephritis IgA Type, Nephropathy IgA Type

Interventions

  • Drug: AtrasentanDrug

    * 104 Weeks - Film-coated tablet * Other Names: Atrasentan Hydrochloride ABT-627

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Proteinuria at Week 36Time frame: Baseline and 36 weeks

Locations

23 sites in 8 countries. Site status is shown where the registry gives one.

  • Hackensack Meridian Health

    Neptune City, New Jersey · Not yet recruiting

  • Cincinnati Childrens Hospital MC

    Cincinnati, Ohio · Not yet recruiting

  • University of Oklahoma Health Science Center

    Oklahoma City, Oklahoma · Not yet recruiting

  • University of Tennessee Health Science Center- Le Bonheur Research Center

    Memphis, Tennessee · Not yet recruiting

  • Novartis Investigative Site

    Beijing, China · Recruiting

  • Novartis Investigative Site

    Xi'an, China · Recruiting

  • Novartis Investigative Site

    Medellín, Antioquia, Colombia · Recruiting

  • Novartis Investigative Site

    Barranquilla, Atlántico, Colombia · Recruiting

  • Novartis Investigative Site

    Bron, France · Recruiting

  • Novartis Investigative Site

    Nantes, France · Recruiting

  • Novartis Investigative Site

    Paris, France · Recruiting

  • Novartis Investigative Site

    Toulouse, France · Recruiting

  • Novartis Investigative Site

    Chiba, Japan · Recruiting

  • Novartis Investigative Site

    Fukuoka, Japan · Recruiting

  • Novartis Investigative Site

    Nagoya, Aichi-ken, Japan · Recruiting

  • Novartis Investigative Site

    Kanazawa, Ishikawa-ken, Japan · Recruiting

  • Novartis Investigative Site

    Seoul, Seoul, South Korea · Recruiting

  • Novartis Investigative Site

    Barcelona, Spain · Recruiting

  • Novartis Investigative Site

    Madrid, Spain · Recruiting

  • Novartis Investigative Site

    Madrid, Spain · Recruiting

  • Novartis Investigative Site

    Cadiz, Andalusia, Spain · Recruiting

  • Novartis Investigative Site

    Taipei, Taiwan · Recruiting

  • Novartis Investigative Site

    Taoyuan, Taiwan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.